Shuanglian Li

机构：Children's Hospital of Chongqing Medical University, Chongqing Medical University

发表论文 49 篇 · 总被引 2228 次 · h-index 18

代表论文

• Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial (2021 · Cancer Discovery · 被引 224)
• Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions. (2019 · Journal of Clinical Oncology · 被引 60)
• Taletrectinib in ROS1 + Non–Small Cell Lung Cancer: TRUST (2025 · Journal of Clinical Oncology · 被引 55)
• TRUST-II: a global phase II study of taletrectinib in ROS1 -positive non-small-cell lung cancer and other solid tumors (2023 · Future Oncology · 被引 33)
• Indirect comparison of TAK-788 vs real-world data outcomes in refractory non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions. (2020 · Journal of Clinical Oncology · 被引 21)
• Petrogenesis and Mineralization of Two‐Stage A‐Type Granites in Jiuyishan, South China: Constraints from Whole‐rock Geochemistry, Mineral Composition and Zircon U‐Pb‐Hf Isotopes (2019 · Acta Geologica Sinica - English Edition · 被引 21)